New hope for Tough-to-Treat bile duct cancer
Disease control
Recruiting now
This study is testing whether a new drug called GNS561 works better when combined with an existing drug, trametinib, for people with advanced bile duct cancer that has a specific genetic change (KRAS mutation) and has stopped responding to standard chemotherapy. The main goals ar…
Phase: PHASE1, PHASE2 • Sponsor: Genfit • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC